[1] Mutanen A, Heikkil P, Lohi J,et al.Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. J Hepatol,2014, 60:183-190. [2] Fisher FM, Chui PC, Nasser IA, et al.Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.Gastroenterology, 2014,147:1073-1083. [3] Jiang S, Yan C, Fang QC, et al. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein esponse and counteracts endoplasmic reticulum stress-induced hepatic steatosis.J Biol Chem,2014,289:29751 -29765. [4] Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care,2013, 36: 145-149. [5] Dushay J, Chui PC, Gopalakrishnan GS,et al.Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology, 2010,139:456- 463. [6] Kim KH, Lee MS.FGF21 as a Stress Hormone: The roles of FGF21 in stress adaptation and the treatment of metabolic diseases. Diabetes Metab J,2014,38: 245-251. [7] 周婷婷,秦波,郑天鹏,等.非酒精性脂肪肝患者血浆FGF21水平及与肥胖、胰岛素抵抗关系研究.第三军医大学学报,2010,:265-268. [8] Lj H,Fang Q,Gao F,et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.J Hepatol,2010, 53:934-940. [9] Li H, Dong K, Fang Q,et al.High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China.J Hepatol, 2013,58:557-563. [10] Xu P, Zhang Y, Liu Y,et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicol Appl Pharmacol,2016,290:43-53. [11] 陈珺明,田淑霞,邢练军,等.基质金属蛋白酶纤溶系统在大鼠酒精性肝纤维化形成中的作用.世界华人消化杂志,2013;21:1595-1601. [12] Miller AM, Horiguchi N, Jeong WI, et al. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res,2011,35: 787-793. [13] Li H, Zhang J, Jia W.Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology.Front Med,2013,7:25-30. [14] Zhu S, Ma L, Wu Y, et al. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. Acta Biochim Biophys Sin (Shanghai), 2014,46: 1041- 1048. [15] Ye X, Qi J, Ren G, et al. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice.Endocrine, 2015,49:683-692. [16] Xu P, Ye X, Zhang Y, et al. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes. J Diabetes Complications, 2015,29:5-12. [17] 杨美,郭晓东,周光德,等.血清FGF-21水平与非酒精性脂肪性肝病的相关性.肝脏,2015,20:686-690. [18] Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.Diabetes. 2010,59: 2781-2789. [19] So WY, Cheng Q, Chen L,et al. High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling.Diabetes,2013,62:3751- 3759. [20] 赵翠青.分泌型成纤维细胞生长因子21和19/15在酒精性肝病中的作用调节机制.吉林:吉林大学,2015. |